Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs MBRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: CAPR 4 – 1 MBRX (1 Tie) Matrix Metrics: CAPR 4 – 4 MBRX

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Moleculin Biotech, Inc. (MBRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas MBRX carries 35.5/100 (SELL) at $7.48 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MBRX currently prints a higher short-term Unified Composite Score (35.5/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-7.9% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both CAPR (28.0/100 SELL) and MBRX (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs MBRX
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
MBRX NASDAQ
Moleculin Biotech, Inc.
Pharmaceutical Preparations
$7.48
-4.96% 1D
Market Cap $7.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.61β · 7732% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 24.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (506.4% over 20 days), RSI 66
RSI-14: 66.1 · SMA20: $7.88 · SMA50: $3.49

6-Pillar Scorecard Institutional Category Breakdown (CAPR 4 – 1 MBRX)

Columns: Metric · CAPR · MBRX
1. Valuation Multiples CAPR
Forward P/E 78.7x N/M
Trailing P/E 78.7x 0.0x
PEG Ratio 0.38x N/M
EV / Revenue 57.8x N/M
2. Growth & Scale CAPR
Revenue Growth (YoY) -7.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $595.4M $7.9M
3. Profitability & Quality CAPR
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -100.5% -1371.6%
4. Balance Sheet & Cash Flow MBRX
Cash Generation (TTM) -$146M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $48M Net Debt (0.44x D/E) $10.0M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 637.1% (89th %ile) N/A (N/A)
Put/Call OI Skew 1.57x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (4) vs MBRX (4)
Institutional Metric CAPR MBRX Criterion Row Edge
Market Capitalization
Scale
$595.4M $7.9M Larger Scale CAPR
Trailing P/E Ratio
Valuation
78.7x 0.0x Lower Multiple MBRX
Forward P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Revenue Growth (YoY)
Growth
-7.9% +0.0% Higher Growth MBRX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-100.5% -1371.6% Higher ROE CAPR
52-Week Range Position
Momentum
15% ($3–$40) 73% ($0–$10) Stronger Trend MBRX
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 4.61β · 7732% Vol Lower Realized Risk CAPR
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 35.5 / 100 (SELL) Higher Composite MBRX
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) N/A ($10.0M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBRX +2541.39 pp
CAPR: +26.23% · MBRX: +2567.62%
3M Horizon MBRX +1106.4 pp
CAPR: +19.63% · MBRX: +1126.03%
6M Horizon MBRX +325.08 pp
CAPR: -70.58% · MBRX: +254.5%
1Y Horizon MBRX +1501.15 pp
CAPR: +46.79% · MBRX: +1547.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAPR vs MBRX. Trailing 12-month operating profitability (CAPR 0.0% vs MBRX 0.0%) and valuation multiples (CAPR 78.7x vs MBRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CAPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-100.5% · 78.7x
MBRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-1371.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MBRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs MBRX Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Moleculin Biotech, Inc. (MBRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas MBRX carries 35.5/100 (SELL) at $7.48 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MBRX currently prints a higher short-term Unified Composite Score (35.5/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-7.9% vs. +0.0% YoY). Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both CAPR (28.0/100 SELL) and MBRX (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

CAPR leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with MBRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CAPR generates $11M in USD-normalized revenue versus N/A for MBRX. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MBRX.

CAPR screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas MBRX trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus MBRX (-1371.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, MBRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.61β · 7732% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.